Option chain shows key data for LIFCO AB SHARE AK B by Lifco AB's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for LIFCO AB SHARE AK B by Lifco AB.

LIFCO AB SHARE AK B by Lifco AB (OTC:LFABF) Stock, Option Chain

LIFCO AB SHARE AK B by Lifco AB

WIIM

AMGN

Amgen shares are trading lower following the results of its Phase 2 study with MariTide in obesity.

Kohl's shares are trading lower after the company reported worse-than-expected Q3 EPS and sales, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%.

Keybanc analyst Jason Celino maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Overweight and raises the price target from $62 to $74.

News

Price Target

Analyst Ratings

GTLB

Keybanc Maintains Overweight on GitLab, Raises Price Target to $74

Novo Nordisk and Eli Lilly shares are trading higher after the Biden-Harris administration proposed a new step to expand coverage of anti-obesity medications for Medicare and Medicaid beneficiaries.

Guidance

Canopy Growth Board Reaffirms Confidence In Company's Strategic Direction

LDTC

LeddarTech Achieves ISO/IEC 27001 Certification, Strengthening Cybersecurity Framework

Keybanc analyst Justin Patterson maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and raises the price target from $38 to $55.

GLBE

Keybanc Maintains Overweight on Global E Online, Raises Price Target to $55

Wells Fargo initiates coverage on Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) with a Equal-Weight rating and announces Price Target of $165.

Initiation

Wells Fargo Initiates Coverage On Thomson Reuters with Equal-Weight Rating, Announces Price Target of $165

AVXL

Anavex Life Sciences Submits Blarcamesine Marketing Authorization Application To EMA For Alzheimer's Disease Treatment Approval

Management

Canopy Growth Names Current Board Member Luc Mongeau As Its Next CEO, Effective January 6, 2025

SL Green Realty Enters Contract To Purchase 500 Park Avenue For $130M

DCGO

DocGo Secures Two-Year Contract With Major Texas Health System For Medical Transportation Services

The FDA will review the updated sBLA within four months of submission. Theratechnologies therefore expects a decision around the end of March 2025. The new formulation is patent protected in the U.S. until 2033.

THTX

Theratechnologies Resubmits Supplemental Biologics License Application To FDA For F8 Formulation Of Tesamorelin

Abercrombie & Fitch Increases Full Year Outlook To Net Sales Growth Outlook From 12% - 13% To 14% -15%; Sees Q4 Net Sales To Grow 5% - 7%

Guggenheim analyst Robert Drbul upgrades Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Neutral to Buy and announces $30 price target.

Upgrades

CPRI

Guggenheim Upgrades Capri Holdings to Buy, Announces $30 Price Target

Wells Fargo analyst Matthew Akers upgrades Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) from Equal-Weight to Overweight and lowers the price target from $157 to $147.

SAIC

Wells Fargo Upgrades Science Applications Intl to Overweight, Lowers Price Target to $147

CGTX

Cognition Therapeutics Announces Completion of Final Visits In Phase 2 SHIMMER Study Of CT1812 For Dementia With Lewy Bodies

In his new role, Ball will serve on the company's executive leadership team and continue to report to Scott Lipesky, Executive Vice President and Chief Operating Officer.
Lipesky, who served as the company's CFO since 2017, was promoted to COO in May 2023, and will remain in that role, leading the company's global operations and growth strategies, while driving financial discipline, capital allocation and efficiency.
&nbsp;

Abercrombie & Fitch Names Robert Ball As CFO, Effective November 20, 2024

ifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) (the "Company" or "Lifeway"), the leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, today provided additional information regarding the reasons that its Board of Directors rejected the revised unsolicited proposal made on November 15, 2024 by Danone North America PBC ("Danone") to acquire all the shares of Lifeway that it does not already own for $27.00 per share.
The Board determined that Danone's $27.00 per share proposal substantially undervalues the Company. The Board is not, however, opposed to the sale of the Company at any price.
The Board has carefully evaluated the Company's standalone plan&nbsp;and believes it has strong potential to provide superior value to all shareholders as compared to Danone's revised proposal. The Board takes its fiduciary duties seriously and is committed to acting in the best interests of all of the Company's shareholders and other stakeholders.

DANOY

LWAY

Lifeway Foods Rejects Danone's $27 Per Share Acquisition Proposal, Citing Undervaluation Of The Company

Earnings

Abercrombie & Fitch Q3 EPS $2.50 Up From $1.83 YoY, Sales $1.21B Up From $1.056B YoY

Comments

LIFCO AB SHARE AK B by Lifco AB

LIFCO AB SHARE AK B by Lifco AB (LFABF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga